One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Dynavax Technologies just hit that mark, with a jump from 79 to 82 Tuesday.
This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
While Dynavax Technologies is not near an ideal entry right now, see if it manages to form and break out of a proper base.
Top and bottom line growth moved higher last quarter. Earnings were up 400%, compared to 20% in the prior report. Revenue increased from 16% to 30%.
The company holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, GeneDx Holdings and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
